The central node of molecular transport, hereditary disorder, and metabolic disease network is NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), which is known active in kidney carcinoma and plays roles in tumour development as well as therapeutic resistance [20,21]. This evidence concerns the gene NFKB1 and neoplasm.